Implications of the LIFE trial

Sunil Nadar, Hoong Sern Lim, Gregory Y.H. Lip*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


The recent Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study was conducted in patients with essential hypertension with electrocardiogram evidence of left ventricular hypertrophy. This showed that losartan compared to atenolol resulted in a significant reduction in the primary endpoint of cardiovascular morbidity and mortality, as well as a greater reduction in electrocardiographically-defined left ventricular hypertrophy. Importantly, this was despite a mean blood pressure reduction which was similar in both groups. Furthermore, the atenolol arm was associated with higher incidence of newly diagnosed diabetics. The LIFE study has firmly confirmed a place for losartan (and other angiotensin receptor blockers) in the management of hypertension. Losartan has also been shown to be effective in diabetics and in patients with atrial fibrillation, as well as in left ventricular hypertrophy regression. This trial also raises the possibility that β-blockers should perhaps not be used as first-line monotherapy.

Original languageEnglish
Pages (from-to)871-877
Number of pages7
JournalExpert Opinion on Investigational Drugs
Issue number5
Publication statusPublished - May 1 2003
Externally publishedYes


  • Angiotensin receptor blockers
  • Cardiovascular mortality
  • Hypertension
  • Losartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Implications of the LIFE trial'. Together they form a unique fingerprint.

Cite this